Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

22

Revenue 2014

Daiichi Sankyo

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.

FDA fast-tracks Astellas' Rydapt rival

FDA fast-tracks Astellas' Rydapt rival

If approved, the Japanese pharma group would see its drug not only compete with Rydapt - the first new drug for AML in more than 25 years - but also with Daiichi

Xarelto no better than aspirin in secondary stroke study

Xarelto no better than aspirin in secondary stroke study For years it led the market among NOAC drugs, keeping ahead of Pfizer and Bristol-Myers Squibb’s Eliquis (apixaban) and with Boehringer Ingelheim’s Pradaxa (dabigatran) and Daiichi Sankyo’s

Novartis gets EU nod for leukaemia drug Rydapt

Novartis gets EU nod for leukaemia drug Rydapt The FLT3 inhibitor adds to its US approval in AML

Astellas extends phase III programme for Rydapt rival gilteritinib

Astellas extends phase III programme for Rydapt rival gilteritinib Two other FLT3 inhibitors - Daiichi Sankyo's quizartinib and Arog Pharma's crenolanib - are also in late-stage testing.

Daiichi drug hits mark in shingles pain, but misses in other indications

Daiichi drug hits mark in shingles pain, but misses in other indications Daiichi Sankyo's mirogabalin has shown efficacy in a phase III trial involving patients with post-herpetic neuralgia (PHN), the persistent and often excruciating pain that can follow shingles. ... What is clear however is that the results of the ALDAY

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Digital
Tools for the digital world
The next step for the pharma industry...
How Can We Make Payer Communications Really Sing?
With so many different influences at play in access decisions, how can we make sure we tap into what’s really driving payer decision-making. How do we go beyond the stated...
Harnessing the power of core elements to optimise market access
This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out...

Infographics